Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

Diene, 2014, Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species, Clin Microbiol Infect, 20, 831, 10.1111/1469-0691.12655 Livermore, 2012, Current epidemiology and growing resistance of Gram-negative pathogens, Korean J Intern Med, 27, 128, 10.3904/kjim.2012.27.2.128 Brooke, 2012, Stenotrophomonas maltophilia: an emerging global opportunistic pathogen, Clin Microbiol Rev, 25, 2, 10.1128/CMR.00019-11 Tängdén, 2015, Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control, J Intern Med, 277, 501, 10.1111/joim.12342 Munoz-Price, 2013, Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases, Lancet Infect Dis, 13, 785, 10.1016/S1473-3099(13)70190-7 Falagas, 2014, Deaths attributable to carbapenem-resistant Enterobacteriaceae infections, Emerg Infect Dis, 20, 1170, 10.3201/eid2007.121004 Gupta, 2011, Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention, Clin Infect Dis, 53, 60, 10.1093/cid/cir202 Ito, 2016, Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa, Antimicrob Agents Chemother, 60, 7396, 10.1128/AAC.01405-16 Choi, 2018, Cefiderocol: a novel siderophore cephalosporin, Expert Opin Investig Drugs, 27, 193, 10.1080/13543784.2018.1426745 Tillotson, 2016, Trojan horse antibiotics-a novel way to circumvent Gram-negative bacterial resistance?, Infect Dis, 9, 45 Benedetto Tiz, 2018, Overcoming problems of poor drug penetration into bacteria: challenges and strategies for medicinal chemists, Expert Opin Drug Discov, 13, 497, 10.1080/17460441.2018.1455660 Ito-Horiyama, 2016, Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases, Antimicrob Agents Chemother, 60, 4384, 10.1128/AAC.03098-15 Ito, 2016, In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria, J Antimicrob Chemother, 71, 670, 10.1093/jac/dkv402 Kohira, 2015, In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains, Antimicrob Agents Chemother, 60, 729, 10.1128/AAC.01695-15 Ito A, Toba S, Nishikawa T, et al. S-649266, a novel siderophore cephalosporin: binding affinity to PBP and in vitro bactericidal activity. 25th European Congress of Clinical Microbiology and Infectious Diseases; Copenhagen; April 25–28, 2015. P0250. Tsuji M, Singley C, Horiyama T, et al. S-649266, a novel siderophore cephalosporin: efficacy against Klebsiella pneumoniae producing NDM-1 or KPC in rat lung infection model with recreated humanized exposure profile of 2 gram dose with 1 hour and 3 hours infusion. ID Week; Philadelphia, PA; Oct 8–12, 2014. 248. Tsuji M, Hackel M, Yamano Y, Echols R, Sahm D. Surveillance of cefiderocol in vitro activity against Gram-negative clinical isolates collected in Europe: SIDERO-WT-2014. European Conference of Clinical Microbiology and Infectious Diseases; Vienna; April 22–25, 2017. 1314. Huntington, 2016, Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial, J Antimicrob Chemother, 71, 2014, 10.1093/jac/dkw053 Wagenlehner, 2016, Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program, Clin Infect Dis, 63, 754, 10.1093/cid/ciw378 Wagenlehner, 2015, Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI), Lancet, 385, 1949, 10.1016/S0140-6736(14)62220-0 Vasquez, 2012, Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study, Curr Med Res Opin, 28, 1921, 10.1185/03007995.2012.748653 Stadler, 2018, Transmission of ESBL-producing Enterobacteriaceae and their mobile genetic elements - identification of sources by whole genome sequencing: study protocol for an observational study in Switzerland, BMJ Open, 8, e021823, 10.1136/bmjopen-2018-021823 2016 Soto, 2014, Importance of biofilms in urinary tract infections: new therapeutic approaches, Adv Biol, 13, 543974 Hancock, 2008, The ferric yersiniabactin uptake receptor FyuA is required for efficient biofilm formation by urinary tract infectious Escherichia coli in human urine, Microbiology, 154, 167, 10.1099/mic.0.2007/011981-0 Rosenthal, 2017 Brown, 2013, Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection, Antimicrob Agents Chemother, 57, 2326, 10.1128/AAC.02176-12